Celmatix
Latest round
- Series A
Last raised
- Mar 2012
Total raised
- $2.3M
Investors
- 1
About Celmatix
Celmatix Inc is a biotechnology company focused on women's health, developing innovative therapeutics for conditions such as ovarian dysfunction.Founded in 2010 and headquartered in New York, US, Celmatix Inc specializes in therapeutics for women's health, particularly targeting ovarian dysfunction. The company was founded by Piraye Beim, who has a history in the biotech sector.Celmatix Inc. specializes in innovative therapeutics focused on women's health, particularly in addressing conditions related to ovarian dysfunction. The company’s primary offerings include drug programs targeting endometriosis, polycystic ovary syndrome (PCOS), and ovarian aging. Their pipeline features a novel AMH receptor agonist, which aims to improve ovarian health, as well as an oral FSH receptor agonist designed to enhance fertility treatment outcomes. Additionally, Celmatix has developed an immunotherapy for endometriosis and is working on a Jun-N-terminal kinase (JNK) inhibitor to address pain and inflammation associated with various women's health indications.Celmatix operates on a revenue model that leverages partnerships and grants, particularly with governmental agencies such as the Advanced Research Projects Agency for Health (ARPA-H).5 mn award to support its ovarian aging program. Revenue generation is expected to occur through collaborations with pharmaceutical companies, healthcare providers, and potentially through direct sales of therapeutics once they reach market approval. The company’s drug programs indicate a focus on B2B transactions with healthcare institutions and direct-to-consumer models once products are commercially available.Celmatix is actively working on several new products, including a novel AMH receptor agonist and an oral FSH receptor agonist aimed at improving fertility treatment outcomes. The company is also looking to expand its presence in Brazil and other geographical regions with unmet needs in women's health within the next few years.76 mn will support these initiatives, allowing for further development of their drug programs and potential market introductions.
Who invested in Celmatix
1 investor across 2 rounds
See all investors in Celmatix
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Celmatix
Who invested in Celmatix?
Celmatix has 1 investor on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Celmatix raised?
Celmatix has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Celmatix last raise money?
Celmatix's most recent round on record is a Series A, in Mar 2012.
What does Celmatix do?
Celmatix Inc is a biotechnology company focused on women's health, developing innovative therapeutics for conditions such as ovarian dysfunction.
Where is Celmatix headquartered?
Celmatix is headquartered in New York, US.
Which VCs invest in companies like Celmatix?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Celmatix's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Celmatix? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.